Everything below concerns eumelanin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
=== Before modelling === Most tertiary structure modelling methods, such as Rosetta, are optimized for modelling the tertiary structure of single protein domains. A step called domain parsing, or domain boundary prediction, is usually done first to split a protein into potential structural domains. As with the rest of tertiary structure prediction, this can be done comparatively from known structures or ab initio with the sequence only (usually by machine learning, assisted by covariation). The structures for individual domains are docked together in a process called domain assembly to form the final tertiary structure.
Δp is the pressure difference between the two ends, L is the length of pipe, μ is the dynamic viscosity, Q is the volumetric flow rate, R is the pipe radius, A is the cross-sectional area of pipe. The equation does not hold close to the pipe entrance. The equation fails in the limit of low viscosity, wide and/or short pipe. Low viscosity or a wide pipe may result in turbulent flow, making it necessary to use more complex models, such as the Darcy–Weisbach equation. The ratio of length to radius of a pipe should be greater than 1/48 of the Reynolds number for the Hagen–Poiseuille law to be valid. If the pipe is too short, the Hagen–Poiseuille equation may result in unphysically high flow rates; the flow is bounded by Bernoulli's principle, under less restrictive conditions, by
== Structure == The typical size of the nanocapsule used for various applications ranges from 10-1000 nm. However, depending on the preparation and use of the nanocapsule, the size will be more specific. Nanocapsule structure consists of nanovesicular system that is formed in a core-shell arrangement. The shell of a typical nanocapsule is made of a polymeric membrane or coating. The type of polymers used is of biodegradable polyester, as nanocapsules are often used in biological systems. Poly-e-caprolactone (PCL), poly(lactide) (PLA), and poly(lactide-co-glicolide) (PLGA) are typical polymers used in nanocapsule formation. Other polymers include thiolated poly(methacrylic acid) and poly(N-vinyl Pyrrolidone). As synthetic polymers have proven to be more pure and reproducible when compared naturally occurring polymers, they are often preferred for the construction nanocapsules. However, some natural occurring polymers such as chitosan, gelatin, sodium alginate, and albumin are used in some drug delivering nanocapsules. Other nanocapsule shells include liposomes, along with polysaccharides and saccharides. Polysaccharides and saccharides are used due to their non-toxicity and biodegradability. They are attractive to use as they resemble biological membranes. The core of a nanocapsule is composed of an oil surfactant that is specifically selected to coordinate with the selected drug within the polymeric membrane. The specific oil used must be highly soluble with the drug, and non-toxic when used in a biological environment.
Sources: en.wikipedia.org
=== Use in special populations === Chloramphenicol is metabolized by the liver to chloramphenicol glucuronate (which is inactive). In liver impairment, the dose of chloramphenicol must therefore be reduced. No standard dose reduction exists for chloramphenicol in liver impairment, and the dose should be adjusted according to measured plasma concentrations. The majority of the chloramphenicol dose is excreted by the kidneys as the inactive metabolite, chloramphenicol glucuronate. Only a tiny fraction of the chloramphenicol is excreted by the kidneys unchanged. Plasma levels should be monitored in patients with renal impairment, but this is not mandatory. Chloramphenicol succinate ester (an intravenous prodrug form) is readily excreted unchanged by the kidneys, more so than chloramphenicol base, and this is the major reason why levels of chloramphenicol in the blood are much lower when given intravenously than orally.
The most controversial of these responses by Ja Rule was leaked in April 2003 in the track Loose Change; in which Ja Rule directly attacked Eminem and Dr. Dre for their affiliation with 50 Cent, notably aiming several insults at Eminem's daughter Hailie. On Eminem's 2005 track "Like Toy Soldiers" he mentioned how he had tried to coerce 50 Cent into ending his feud with Ja Rule, until Ja Rule leaked his diss track attacking him and his daughter. Eminem and D12 quickly responded with Hailie's revenge, a diss track that was critically lauded as one of the best in the genre for its aggression and ferocity. Further attacks came in the form of other rappers such as Obie Trice and Busta Rhymes, the latter of whom joined 50 Cent and Eminem on a remake of Tupac Shakur's "Hail Mary". In the track; Eminem proclaimed a narrative that drew criticism towards Ja Rule for his supposed influence of Tupac's image to benefit himself. In another move to damage Ja Rule's contributions to other collaborative efforts, Eminem later barred him from appearing on any remixed posthumous tracks by Tupac Shakur on the 2004 album Loyal to the Game. Former D12 affiliate Royce Da 5'9 who was involved with an ongoing feud with the group; took side with Murder Inc on his diss track Malcolm X in which he attacked both D12 and G-Unit, even threatening to sign with Murder Inc. Following the release of his track, Royce later made amends with Proof of D12 following the two being arrested in connection to a nightclub fight.
== Organisational structure == The NNPC's business operations are managed through Strategic Business and Corporate Services Units (SBUs/CSUs) in diverse locations across Nigeria. The NNPC Group comprises the NNPC Board, the group managing director's office, Five directorates as listed below. Each of the directorate is headed by an executive vice president (EVP). Its divisions are headed by chiefs, while its subsidiary companies are headed by managing directors. NNPC has several subsidiaries, two partly owned subsidiaries and 16 associated companies. Directorates:
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.